InsiderTrades.com logo
Gina Mazzariello net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Gina Mazzariello Biography and Net Worth

Insider of Amylyx Pharmaceuticals

Gina M. Mazzariello joined Amylyx in 2022 as Chief Legal Officer and General Counsel bringing more than 20 years of experience in the healthcare industry. Prior to Amylyx, Gina was with Boehringer Ingelheim USA, Inc., where she held positions of increasing responsibility providing legal counsel to support BI’s global human pharmaceuticals business. Most recently, Gina served as Vice President, Human Pharma Business Law, where she led a team of lawyers and paraprofessionals to support all aspects of BI’s U.S. prescription pharmaceuticals business, including research, clinical development, and sales and marketing. She earned her Bachelor’s degree from Syracuse University and her J.D. from Harvard Law School. Gina has an established track record of commitment to diversity, equity, and inclusion, most recently having served as the President of the Board of Directors for the Lawyers Collaborative for Diversity, a non-profit organization focused on increasing diversity in the practice of law in Connecticut. 

What is Gina Mazzariello's net worth?

The estimated net worth of Gina Mazzariello is at least $2.15 million as of September 30th, 2025. Mazzariello owns 148,141 shares of Amylyx Pharmaceuticals stock worth more than $2,146,563 as of December 4th. This net worth estimate does not reflect any other investments that Mazzariello may own. Additionally, Mazzariello receives a salary of $689,260.00 as Insider at Amylyx Pharmaceuticals. Learn More about Gina Mazzariello's net worth.

How old is Gina Mazzariello?

Mazzariello is currently 53 years old. There are 4 older executives and no younger executives at Amylyx Pharmaceuticals. The oldest executive at Amylyx Pharmaceuticals is Dr. Camille L. Bedrosian M.D., Chief Medical Officer, who is 71 years old. Learn More on Gina Mazzariello's age.

What is Gina Mazzariello's salary?

As the Insider of Amylyx Pharmaceuticals, Inc., Mazzariello earns $689,260.00 per year. There are 3 executives that earn more than Mazzariello. The highest earning executive at Amylyx Pharmaceuticals is Mr. Joshua B. Cohen, Co-Founder, Co-CEO & Director, who commands a salary of $1,080,000.00 per year. Learn More on Gina Mazzariello's salary.

How do I contact Gina Mazzariello?

The corporate mailing address for Mazzariello and other Amylyx Pharmaceuticals executives is , , . Amylyx Pharmaceuticals can also be reached via phone at 617-682-0917 and via email at [email protected]. Learn More on Gina Mazzariello's contact information.

Has Gina Mazzariello been buying or selling shares of Amylyx Pharmaceuticals?

Gina Mazzariello has not been actively trading shares of Amylyx Pharmaceuticals during the past quarter. Most recently, Gina Mazzariello sold 8,828 shares of the business's stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $14.58, for a transaction totalling $128,712.24. Following the completion of the sale, the insider now directly owns 148,141 shares of the company's stock, valued at $2,159,895.78. Learn More on Gina Mazzariello's trading history.

Who are Amylyx Pharmaceuticals' active insiders?

Amylyx Pharmaceuticals' insider roster includes Camille Bedrosian (Insider), Joshua Cohen (Co-Founder), Joshua Cohen (CEO), James Frates (CFO), M Jr (Director), Justin Klee (CEO), Justin Klee (Co-Founder), Gina Mazzariello (Insider), Daphne Quimi (Director), Patrick Yeramian (Insider), and Bernhardt Zeiher (Director). Learn More on Amylyx Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Amylyx Pharmaceuticals?

In the last year, Amylyx Pharmaceuticals insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $37,000.00. In the last year, insiders at the sold shares 13 times. They sold a total of 169,893 shares worth more than $1,666,686.16. The most recent insider tranaction occured on December, 1st when insider Camille L Bedrosian sold 6,580 shares worth more than $94,423.00. Insiders at Amylyx Pharmaceuticals own 12.3% of the company. Learn More about insider trades at Amylyx Pharmaceuticals.

Information on this page was last updated on 12/1/2025.

Gina Mazzariello Insider Trading History at Amylyx Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/30/2025Sell8,828$14.58$128,712.24148,141View SEC Filing Icon  
2/24/2025Sell4,169$3.15$13,132.35134,921View SEC Filing Icon  
2/3/2025Sell3,678$3.49$12,836.22139,090View SEC Filing Icon  
5/15/2024Sell10,455$1.88$19,655.40151,477View SEC Filing Icon  
3/5/2024Sell1,540$18.73$28,844.2081,372View SEC Filing Icon  
2/23/2024Sell2,838$18.76$53,240.8846,245View SEC Filing Icon  
2/24/2023Sell3,586$34.49$123,681.1437,414View SEC Filing Icon  
See Full Table

Gina Mazzariello Buying and Selling Activity at Amylyx Pharmaceuticals

This chart shows Gina Mazzariello's buying and selling at Amylyx Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amylyx Pharmaceuticals Company Overview

Amylyx Pharmaceuticals logo
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $14.49
Low: $13.91
High: $14.64

50 Day Range

MA: $14.00
Low: $12.18
High: $15.79

2 Week Range

Now: $14.49
Low: $2.60
High: $16.96

Volume

781,740 shs

Average Volume

1,403,731 shs

Market Capitalization

$1.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A